Newport Beach, United States
CureDuchenne is a global leader in Duchenne research, patient care, and innovation. Founded by Paul and Debra Miller in 2003 after their son was diagnosed with the disease, the company is dedicated to accelerating research, improving care, and empowering the community affected by Duchenne. With the slogan "Together, we WILL cure Duchenne!", CureDuchenne focuses on leveraging donor dollars through fundraising and venture philanthropy to maximize support for promising research into effective treatments for those suffering from Duchenne.
CureDuchenne's commitment to transparency is evident in its core values, as it actively redeploys investment proceeds to support research and other mission-critical programs aimed at finding a cure for Duchenne. The company's efforts are aimed at Education and Health Care industries, with its headquarters located in the United States.
The last known investment and its investors are not publicly available at this time. However, CureDuchenne's dedication to its cause and the impactful work it undertakes make it a compelling candidate for consideration by venture capitalists looking to invest in companies driving positive change in the health and education sectors.
For further information, visit cureduchenne.org.
